Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-214201 · Präparat HOS-155288
Multiorgan hypersensitivity reactions
Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic
Symptoms, DRESS) have been reported rarely in patients treated with levetiracetam. Clinical
manifestations may develop 2 to 8 weeks after starting treatment. These reactions are variable in
expression, but typically present with fever, rash, facial oedema, lymphadenopathies, haematologic
abnormalities and can be associated with involvement of different organ systems, mostly the liver. If
multiorgan hypersensitivity reaction is suspected, levetiracetam should be discontinued.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage eda55acf1b7364e2822fd26eda7705b641379bce3a142b173038200ed864c9d3 · Zeichen 7226–7841 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-214202 · Präparat HOS-155288
The risk of anorexia is higher when levetiracetam is coadministered with topiramate.
In several cases of alopecia, recovery was observed when levetiracetam was discontinued. Bone
marrow suppression was identified in some of the cases of pancytopenia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage 896cb87109bc787c35c15fb4bf5dd975eec9aa31de1e92bda44dfb7fb3ff6787 · Zeichen 7843–8093 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-214203 · Präparat HOS-155288
Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a
few months) and were reversible after treatment discontinuation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage 5c842d2fb185f079fef285a9d38df366a96a830a41d25b742e936d55d109450d · Zeichen 8095–8251 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11–12
HOS-214204 · Präparat HOS-155288
11
Paediatric population
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage b07b5fe2813f39b0769a15480eb92a41dbd29a38217b581b229fd454da936a8b · Zeichen 8303–8328 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-214205 · Präparat HOS-155288
In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with
levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were
treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645
patients have been treated with levetiracetam in placebo-controlled and open label extension studies.
233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these
paediatric age ranges, these data are supplemented with the post-marketing experience of the use of
levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage fedc1a5f0e0c30ef1fe608375aff0dcee15b729856ff083e7adbddf0844db5ae · Zeichen 8330–8940 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-214206 · Präparat HOS-155288
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety
study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age
with epilepsy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage 41ed00d104d19c23174963c54848459e44b443ab02b058444d67ba507e1a8f21 · Zeichen 8942–9158 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-214207 · Präparat HOS-155288
The adverse reaction profile of levetiracetam is generally similar across age groups and across the
approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical
studies were consistent with the safety profile of levetiracetam in adults except for behavioural and
psychiatric adverse reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood
swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal
behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other
age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years,
irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more
frequently than in other age groups or in the overall safety profile.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage 3ccbb326e277875bb9e9adba92b52f6b30b4ee52e2944d22c34697927788270d · Zeichen 9160–10109 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-214208 · Präparat HOS-155288
A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed
the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with
partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from
placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory
Screen Composite score in the per-protocol population. Results related to behavioural and emotional
functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as
measured in a standardised and systematic way using a validated instrument (CBCL – Achenbach
Child Behavior Checklist). However, subjects, who took levetiracetam in the long-term open label
follow-up study, did not experience a worsening, on average, in their behavioural and emotional
functioning; in particular measures of aggressive behaviour were not worse than baseline.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage aab9b1393f1ee52962b6a48a247f24f3046695d57b00c290db52e38b1ded5c57 · Zeichen 10111–11074 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-214209 · Präparat HOS-155288
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 11076–11116 im Abschnitt
Nebenwirkungen · Levetiracetam Accord
Levetiracetam Accord 250 mg film-coated tablets Levetiracetam Accord 500 mg film-coated tablets Levetiracetam Accord 750 mg film-coated tablets Levetiracetam Accord 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-214210 · Präparat HOS-155288
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T02:00:00Z · SHA-256 ec3de1977942bc302d179ba3cf5ac8635c815ee58daca279cdcc4d00ec8f450f · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 11118–11432 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.